SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 91.16 |
| Enterprise Value ($M) | 13.06 |
| Book Value ($M) | 184.27 |
| Book Value / Share | 3.82 |
| Price / Book | 0.49 |
| NCAV ($M) | 160.82 |
| NCAV / Share | 3.33 |
| Price / NCAV | 0.57 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.64 |
| Return on Assets (ROA) | -0.41 |
| Return on Equity (ROE) | -0.50 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 14.25 |
| Current Ratio | 14.25 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 197.17 |
| Assets | 220.62 |
| Liabilities | 36.35 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Flynn James E | 3.78 | -52.98 | |
| 13G/A | Deep Track Capital, LP | 0.00 | -100.00 | |
| 13G | Tang Capital Partners Lp | 9.50 | ||
| 13D/A | Frazier Life Sciences Public Fund, L.P. | 21.40 | 8.50 | |
| 13G/A | Lightspeed Venture Partners Select IV, L.P. | 4.80 | 20.90 | |
| 13G/A | Ra Capital Management, L.p. | 0.00 | -100.00 | |
| 13G/A | Carlyle Group Inc. | 3.80 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 37,200 | 233,436 | 15.94 | |
| 22,458 | 101,581 | 22.11 | |
| 18,744 | 97,766 | 19.17 | |
| 46,937 | 181,423 | 25.87 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| GLUE – Monte Rosa Therapeutics, Inc. | GOSS – Gossamer Bio, Inc. |
| HALO – Halozyme Therapeutics, Inc. | HOWL – Werewolf Therapeutics, Inc. |
| HUMA – Humacyte, Inc. |
Financial data and stock pages provided by
Fintel.io